Vyxeos Liposomal provides optimal benefit when
used for both induction and consolidation therapy2,3
Treatment should be continued as long as the patient continues to benefit or until disease progression, up to a maximum of 2 induction courses and 2 consolidation courses1
To determine the dose and number of vials you will need for each patient, calculate the volume of reconstituted Vyxeos Liposomal required using the following formula:1
Each vial contains 44 mg of daunorubicin and 100 mg of cytarabine1
After reconstitution, the solution contains 2.2 mg/mL daunorubicin and 5 mg/mL cytarabine, encapsulated in liposomes in a fixed combination in a 1:5 molar ratio1
Please refer to the SmPC for dosing considerations with Vyxeos Liposomal1
Please refer to the SmPC for dosing considerations with Vyxeos Liposomal1
Important notice: This site has been created for healthcare professionals only. By entering this site, you are confirming that you are a European healthcare professional. This site contains promotional information.
I CONFIRM THAT I AM A EUROPEAN HEALTHCARE PROFESSIONAL
I AM A UK HEALTHCARE PROFESSIONAL
I AM A US HEALTHCARE PROFESSIONAL
I AM NOT A HEALTHCARE PROFESSIONAL
Please note that this information is intended for healthcare professionals in the UK
Please note that this information is intended for healthcare professionals in the US only
For more information:
By clicking here you will be taken to the European Medicines Agency’s external website
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly through your national medicines side effect reporting system or to Jazz Pharmaceuticals AEreporting@jazzpharma.com. By reporting side effects, you can help provide more information on the safety of this medicine.